{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:06:33Z","timestamp":1790863593740,"version":"4.1.0"},"reference-count":14,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"unspecified","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,8,23]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-vimentin IgG-associated autoimmune encephalitis (AE) is a recently described autoimmune astrocytopathy characterised by relapsing-remitting cerebellar ataxia, brainstem involvement and pyramidal tract lesions. Nevertheless, several key aspects remain poorly elucidated, including the full clinical phenotypic spectrum (particularly peripheral nervous system (PNS) involvement), the interpretation of serological discrepancies and long-term management outcomes. Additionally, the imaging evidence for neuroinflammation and the evidence regarding evolution following treatment remain insufficient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We reported a man in his late 40s who developed a core triad of cerebellar ataxia, pyramidal signs and peripheral neuropathy. Conventional MRI was unremarkable, but cerebrospinal fluid analysis revealed anti-vimentin IgG positivity (titre 1:10) with type III oligoclonal bands while serum was negative.\n                      <jats:sup>18<\/jats:sup>\n                      F-DPA714 positron emission tomography\/MRI showed elevated tracer uptake in the mesial temporal lobe, frontal lobe and brainstem, correlating with clinical signs. After intravenous immunoglobulin induction and ofatumumab maintenance therapy, the patient showed clinical improvement (modified Rankin Scale from 2 to 1) at 3-month follow-up, paralleled by reduced tracer uptake.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This first reported middle-aged male case expands the demographic and phenotypic spectrum of anti-vimentin IgG-associated AE to include PNS involvement. This case highlights the diagnostic value of antibody detection and advanced imaging modalities in atypical presentations of anti-vimentin IgG-associated AE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2026-001557","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:42:48Z","timestamp":1790862168000},"page":"e001557","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Case report of anti-vimentin IgG-associated autoimmune encephalitis: diagnostic challenges and the role of\n                    <sup>18<\/sup>\n                    F-DPA714 PET\/MRI"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0759-1121","authenticated-orcid":false,"given":"Siqi","family":"Tu","sequence":"first","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7428-7153","authenticated-orcid":false,"given":"Sheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanyu","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026100106201826000_8.2.e001557.1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamaneurol.2024.4763","article-title":"Novel Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies","volume":"82","author":"Wan","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026100106201826000_8.2.e001557.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9"},{"key":"2026100106201826000_8.2.e001557.3","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.779","article-title":"Peripheral neuropathy in limbic encephalitis with anti-glutamate receptor antibodies: Case report and systematic literature review","volume":"7","author":"Wei","year":"2017","journal-title":"Brain Behav"},{"key":"2026100106201826000_8.2.e001557.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2024-000912","article-title":"CSF oligoclonal bands in neurological diseases besides CNS inflammatory demyelinating disorders","volume":"7","author":"Ren","year":"2025","journal-title":"BMJ Neurol Open"},{"key":"2026100106201826000_8.2.e001557.5","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-026-04912-7","article-title":"A case of novel meningoencephalomyelitis associated with vimentin IgG autoantibodies","volume":"26","author":"Sun","year":"2026","journal-title":"BMC Neurol"},{"key":"2026100106201826000_8.2.e001557.6","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70107","article-title":"Microglial Activation Visualized by [18F]-DPA714 PET Is a Potential Marker of Severity and Prognosis for Anti-LGI1 Encephalitis","volume":"32","author":"Wang","year":"2025","journal-title":"Eur J Neurol"},{"key":"2026100106201826000_8.2.e001557.7","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.230397","article-title":"Microglial Activation Imaging Using 18F-DPA-714 PET\/MRI for Detecting Autoimmune Encephalitis","volume":"310","author":"Zhang","year":"2024","journal-title":"Radiology"},{"key":"2026100106201826000_8.2.e001557.8","doi-asserted-by":"crossref","first-page":"7592","DOI":"10.1007\/s00415-024-12690-w","article-title":"18F-DPA714 PET\/MRI as a potential imaging tool for detecting possible antibody-negative autoimmune encephalitis: a prospective study","volume":"271","author":"Meng","year":"2024","journal-title":"J Neurol"},{"key":"2026100106201826000_8.2.e001557.9","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-026-13865-3","article-title":"18F-DPA714 PET in MRI-negative autoimmune encephalitis: a supportive approach to aiding neuroinflammation identification, disease severity correlation, and treatment response prediction","volume":"273","author":"Meng","year":"2026","journal-title":"J Neurol"},{"key":"2026100106201826000_8.2.e001557.10","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1007\/s00259-025-07305-z","article-title":"Comparison of 18F-DPA714 PET\/MRI and 18F-FDG PET\/CT in patients with autoimmune encephalitis: a cross-sectional study","volume":"52","author":"Meng","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100106201826000_8.2.e001557.11","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40120-023-00518-0","article-title":"The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment","volume":"12","author":"Hauser","year":"2023","journal-title":"Neurol Ther"},{"key":"2026100106201826000_8.2.e001557.12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ana.27218","article-title":"Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study","volume":"98","author":"Guo","year":"2025","journal-title":"Ann Neurol"},{"key":"2026100106201826000_8.2.e001557.13","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s10072-024-07876-z","article-title":"Efficacy of ofatumumab combined with corticosteroids in the treatment of autoimmune encephalitis: a 6-month cohort study","volume":"46","author":"She","year":"2025","journal-title":"Neurol Sci"},{"key":"2026100106201826000_8.2.e001557.14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1557210","article-title":"Case Report: Efficacy of ofatumumab in refractory anti-NMDAR encephalitis: case series and literature review","volume":"16","author":"Deng","year":"2025","journal-title":"Front Immunol"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2026-001557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:42:50Z","timestamp":1790862170000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2026-001557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjno-2026-001557"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2026-001557","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}